Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simlukafusp alfa + Atezolizumab in Advanced Solid Tumors
NCT03386721Phase 2Terminated
- Sponsor
- Roche
- Start
- Feb 2018
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 15
01
Overview
Phase 2, open-label trial of simlukafusp alfa in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 1 more (17 cohorts), sponsored by Roche. Primary endpoint: Objective Response Rate up to 38 months. Started Feb 2018; status: terminated.
02
Drugs
simlukafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT03386721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386721.